Eli Lilly and Co
NYSE:LLY
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
LLY
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 1 034.78 USD,
Eli Lilly and Co
is
hidden
.
Valuation History
Eli Lilly and Co
LLY looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether LLY usually does or if today's premium is unusual.
Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Eli Lilly and Co.
Fundamental Analysis
LLY Profitability Score
Profitability Due Diligence
Score
LLY Solvency Score
Solvency Due Diligence
Score
Despite the significant buzz around tirzepatide and other diabetes products, their high development and marketing costs could erode profitability if insurance reimbursement or pricing pressures intensify, particularly in today’s cost-conscious healthcare environment.
Tirzepatide’s rapid approvals and robust clinical outcomes in diabetes and obesity treatments position Eli Lilly to capture valuable market share in a high-growth therapeutic area, protecting long-term revenue streams.
Revenue & Expenses Breakdown
Eli Lilly and Co
Balance Sheet Decomposition
Eli Lilly and Co
Eli Lilly and Co
Free Cash Flow Analysis
Eli Lilly and Co
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Eli Lilly and Co
Wall St
Price Targets
LLY Price Targets Summary
Eli Lilly and Co
According to Wall Street analysts, the average 1-year price target for
LLY
is 1 129.89 USD
with a low forecast of 713.1 USD and a high forecast of 1 575 USD.
Dividends
Current shareholder yield for LLY is
hidden
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
LLY
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 1 034.78 USD,
Eli Lilly and Co
is
hidden
.
